paroxetine has been researched along with buspirone in 45 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (13.33) | 18.2507 |
2000's | 16 (35.56) | 29.6817 |
2010's | 23 (51.11) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
Ahman, M; Holmén, AG; Wan, H | 1 |
Cleves, AE; Jain, AN; Kirshner, D; Langham, JJ; Spitzer, R | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ | 1 |
Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Dalvie, D; Loi, CM; Smith, DA | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
Lima, L; Trejo, E; Urbina, M | 1 |
Carpenter, LL; Epperson, CN; McDougle, CJ; Price, LH | 1 |
Adler, DA; Bungay, KM; Romanelli, F | 1 |
Bourin, M; Redrobe, JP | 1 |
Agren, H; Björling, G; Fahlén, T; Landén, M | 1 |
Agren, H; Eriksson, E; Fahlén, T; Landén, M | 1 |
Bourin, M; Hascoët, M; Nic Dhonnchadha, BA | 1 |
Terao, T | 1 |
Aida, R; Akiyama, M; Moriya, T; Shibata, S; Shimomura, H; Takahashi, S; Yoshinobu, Y | 1 |
Gorman, JM | 2 |
Burton, D; Camilleri, M; Chial, HJ; Olden, KW; Stephens, D; Thomforde, G | 1 |
Rickels, K; Rynn, M | 1 |
Jägestedt, M; von Bahr, C | 1 |
Bellew, K; Rickels, K; Rynn, MA; Snyderman, SH | 1 |
Högberg, P; Landén, M; Thase, ME | 1 |
Preskorn, SH | 1 |
Kalgutkar, AS; Obach, RS; Soglia, JR; Zhao, SX | 1 |
Calabrese, JR; Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C | 1 |
Campbell Burton, CA; Gillespie, D; Holmes, J; Knapp, P; Lightbody, CE; Murray, J; Watkins, CL | 1 |
Milanlioglu, A | 1 |
Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C | 1 |
Bijlsma, EY; Chan, JS; Millan, MJ; Olivier, B; Oosting, RS; Veening, JG; Waldinger, MD | 1 |
Akindipe, TO; Ipser, JC; Sager, C; Stein, DJ; Wilson, D | 1 |
Campbell Burton, CA; Chun, HY; Gillespie, D; Holmes, J; Knapp, P; Lewis, SR; Lightbody, CE; Murray, J; Watkins, CL | 1 |
Baandrup, L; Ebdrup, BH; Glenthøj, BY; Gluud, C; Lindschou, J; Rasmussen, JØ | 1 |
Barbui, C; Bighelli, I; Breilmann, J; Castellazzi, M; Cipriani, A; Davies, SJ; Furukawa, TA; Girlanda, F; Guaiana, G; Koesters, M | 1 |
12 review(s) available for paroxetine and buspirone
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.
Topics: 1-Naphthylamine; Adult; Aged; Antidepressive Agents; Buspirone; Child; Clomipramine; Clonazepam; Costs and Cost Analysis; Dopamine Antagonists; Drug Interactions; Drug Tolerance; Fenfluramine; Fluoxetine; Fluvoxamine; Humans; Lithium; Obsessive-Compulsive Disorder; Paroxetine; Risk Assessment; Selective Serotonin Reuptake Inhibitors; Sertraline; Tryptophan | 1996 |
Treatment of generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Cognitive Behavioral Therapy; Cyclohexanols; Follow-Up Studies; Humans; Paroxetine; Psychotherapy; Pyrimidines; Relaxation Therapy; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Pharmacotherapy of generalized anxiety disorder.
Topics: Algorithms; Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Drug Administration Schedule; Humans; Paroxetine; Psychotherapeutic Processes; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2002 |
Treating generalized anxiety disorder.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Cognitive Behavioral Therapy; Cyclohexanols; Humans; Imipramine; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; United States; Venlafaxine Hydrochloride | 2003 |
Paroxetine in the treatment of generalised anxiety disorder.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Benzodiazepines; Buspirone; Delayed-Action Preparations; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 2004 |
Interventions for treating anxiety after stroke.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Buspirone; Humans; Paroxetine; Psychotherapy; Randomized Controlled Trials as Topic; Stroke | 2011 |
Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release?
Topics: Animals; Antidepressive Agents; Aza Compounds; Brain; Bridged Bicyclo Compounds, Heterocyclic; Bupropion; Buspirone; Cyclohexanols; Disease Models, Animal; Dopamine; Female; Humans; Indoles; Male; Norepinephrine; Paroxetine; Pyridines; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Synaptic Transmission; Venlafaxine Hydrochloride | 2014 |
Pharmacotherapy for anxiety and comorbid alcohol use disorders.
Topics: Alcohol-Related Disorders; Anxiety; Anxiety Disorders; Buspirone; Comorbidity; Desipramine; Humans; Paroxetine; Phobia, Social; Publication Bias; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Stress Disorders, Post-Traumatic | 2015 |
Interventions for treating anxiety after stroke.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Buspirone; Depression; Humans; Middle Aged; Paroxetine; Pilot Projects; Psychotherapy; Randomized Controlled Trials as Topic; Relaxation Therapy; Stroke | 2017 |
Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.
Topics: Adult; Antidepressive Agents; Aspartic Acid; Benzodiazepines; Buspirone; Carbamazepine; Ethylamines; Flumazenil; Homeopathy; Humans; Imidazoles; Lithium Compounds; Melatonin; Paroxetine; Pregabalin; Progesterone; Pyridines; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome; Sulfides; Withholding Treatment | 2018 |
Benzodiazepines versus placebo for panic disorder in adults.
Topics: Adult; Aged; Agoraphobia; Benzodiazepines; Buspirone; Humans; Imipramine; Middle Aged; Numbers Needed To Treat; Panic Disorder; Paroxetine; Patient Dropouts; Placebos; Propranolol; Randomized Controlled Trials as Topic; Remission Induction; Young Adult | 2019 |
6 trial(s) available for paroxetine and buspirone
Article | Year |
---|---|
A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression.
Topics: Adult; Aged; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Placebo Effect; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Treatment Outcome | 1998 |
Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Buspirone; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological | 1999 |
Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health.
Topics: Adult; Buspirone; Colon; Cyclohexanols; Double-Blind Method; Fasting; Female; Gastric Emptying; Gastrointestinal Motility; Humans; Male; Middle Aged; Paroxetine; Postprandial Period; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Tomography, Emission-Computed, Single-Photon; Venlafaxine Hydrochloride | 2003 |
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.
Topics: Buspirone; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Norway; Paroxetine; Placebos; Psychiatric Status Rating Scales; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sexual Dysfunctions, Psychological; Surveys and Questionnaires; Sweden | 2005 |
A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression.
Topics: Buspirone; China; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Remission Induction; Risperidone; Selective Serotonin Reuptake Inhibitors; Thyroid Hormones; Trazodone; Valproic Acid | 2011 |
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Risperidone; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
27 other study(ies) available for paroxetine and buspirone
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physical binding pocket induction for affinity prediction.
Topics: Binding Sites; Ligands; Models, Molecular; Neural Networks, Computer; Peptide Fragments; Protein Binding; Receptor, Serotonin, 5-HT1A | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results | 2011 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Serotonin turnover rate, [3H]paroxetine binding sites, and 5-HT1A receptors in the hippocampus of rats subchronically treated with clonazepam.
Topics: Animals; Binding Sites; Buspirone; Clonazepam; Dose-Response Relationship, Drug; Hippocampus; Male; Paroxetine; Radioligand Assay; Rats; Rats, Sprague-Dawley; Serotonin; Time Factors | 1995 |
Possible paroxetine-induced bruxism.
Topics: Adult; Anti-Anxiety Agents; Bruxism; Buspirone; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors | 1996 |
Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Topics: Animals; Antidepressive Agents; Buspirone; Citalopram; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Exercise Test; Fluoxetine; Fluvoxamine; Male; Mice; Motor Activity; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming | 1998 |
The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test.
Topics: Animals; Anti-Anxiety Agents; Buspirone; Dose-Response Relationship, Drug; Drug Interactions; Male; Mice; Paroxetine; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors | 2000 |
Female sexual dysfunction and antidepressant use.
Topics: Amantadine; Antidepressive Agents; Buspirone; Citalopram; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Meta-Analysis as Topic; Paroxetine; Personality Inventory; Placebos; Sexual Dysfunctions, Psychological; Treatment Outcome | 2001 |
Extended action of MKC-242, a selective 5-HT(1A) receptor agonist, on light-induced Per gene expression in the suprachiasmatic nucleus in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Buspirone; Cell Cycle Proteins; Circadian Rhythm; Diazepam; Dioxanes; Dioxoles; GABA Modulators; Gene Expression Regulation; In Situ Hybridization; Light; Male; Mice; Motor Activity; Nuclear Proteins; Paroxetine; Period Circadian Proteins; Piperazines; Pyridines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists; Suprachiasmatic Nucleus; Transcription Factors | 2002 |
[Combination of serotonergic agents resulted in severe adverse effects].
Topics: Antidepressive Agents, Second-Generation; Buspirone; Cytochrome P-450 CYP2D6; Depression; Drug Interactions; Drug Therapy, Combination; Female; Humans; Middle Aged; Papaverine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Serotonin Syndrome; Vasodilator Agents | 2004 |
Mania in a case of polypsychopharmacology: pharmacodynamic and pharmacokinetic considerations. Do you believe in magic?
Topics: Adjustment Disorders; Adolescent; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Buspirone; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Electroconvulsive Therapy; Female; Humans; Paroxetine; Psychotropic Drugs; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Suicide, Attempted | 2007 |
Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.
Topics: Acetaminophen; Binding Sites; Buspirone; Carbamazepine; Diclofenac; Diphenhydramine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hepatocytes; Humans; Indomethacin; Meloxicam; Microsomes, Liver; Molecular Structure; Paroxetine; Piperazines; Propranolol; Raloxifene Hydrochloride; Simvastatin; Structure-Activity Relationship; Thiazines; Thiazoles; Ticrynafen; Toxicity Tests; Triazoles | 2008 |
Paroxetine-induced severe sleep bruxism successfully treated with buspirone.
Topics: Adult; Antidepressive Agents, Second-Generation; Buspirone; Female; Humans; Paroxetine; Serotonin 5-HT1 Receptor Agonists; Sleep Bruxism | 2012 |